Recent Progress with Vaccines Against Epstein-Barr Virus Infection

  • M. A. Epstein
Part of the NATO ASI Series book series (NSSA, volume 179)


For well over a decade there has been strong evidence indicating that Epstein-Barr (EB) virus, one of the six human herpesviruses, forms an essential link in the complicated chain of events leading to the development of two human cancers (reviewed in Epstein and Achong, 1979), endemic Burkitt’s lymphoma (BL) (Burkitt, 1963) and undifferentiated nasopharyngeal carcinoma (NPC) (Shanmugaratnam, 1971). More recently, it has emerged that the virus also seems to be causally linked to the malignant lymphomas which arise with undue frequency in immunodepressed individuals (Purtillo, 1984).


Infectious Mononucleosis Recombinant Vaccinia Virus Varicella Virus Undifferentiated Nasopharyngeal Carcinoma Cottontop Tamarin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allison, A.C. and Byars, N.E., 1986, An adjuvant formulation that selectively elicits the formation of antibodies of protective isotype and cell mediated immunity, J. Immunol.Methods, 95: 157.PubMedCrossRefGoogle Scholar
  2. Beisel, C., Tanner, J., Matsuo, T., Thorley-Lawson, D., Kezdy, F. and Kieff, E., 1985, Two major outer envelope glycoproteins of Epstein-Barr virus encoded by the same gene, J.Virol., 54: 665.PubMedGoogle Scholar
  3. Biggin, M., Farrell, P.J. and Barrell, B.G., 1984, Transcription and DNA sequence of the Bam HIL fragment of B95-8 Epstein-Barr Virus, EMBO.J., 3: 1083.PubMedGoogle Scholar
  4. Burkitt, D., 1963, A lymphoma syndrome in tropical Africa, in: “International Review of Experimental Pathology”, G.W. Richter and M.A. Epstein, eds., Academic Press, New York.Google Scholar
  5. Cammoun, M., Hoerner, G.V. and Mourali, N., 1974, Tumors of the nasopharynx in Tunisia: an anatomic and clinical study based on 143 cases, Cancer, 3: 184.CrossRefGoogle Scholar
  6. Churchill, A.E., Payne, L.N. and Chubb, R.C., 1969, Immunization against Marek’s disease using a live attenuated virus, Nature, 221: 744.PubMedCrossRefGoogle Scholar
  7. Cleary, M.L., Epstein, M.A., Finerty, S., Dorfman, R.F., Bornkamm, G.W., Kirkwood, J.K., Morgan, A.J. and Sklar, J., 1985, Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B cell clones, Science, 228: 722.PubMedCrossRefGoogle Scholar
  8. Clifford, P., 1970, A review: On the epidemiology of nasopharyngeal carcinoma, Int.J.Cancer, 5: 287.PubMedCrossRefGoogle Scholar
  9. Conway, M., Morgan, A. and Mackett, M., 1988, Expression of Epstein-Barrvirus antigen gp340/220 in mouse fibroblasts using a bovine papilloma virus vector, submitted to pressGoogle Scholar
  10. David, E.M. and Morgan, A.J., 1988, Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography, J. Immunol. Methods, 108: 231.PubMedCrossRefGoogle Scholar
  11. Deinhardt, F. and Jilg, W., 1986, Vaccines against hepatitis, Ann. Inst. Pasteur, Virol., 137E:79.Google Scholar
  12. Doll, R. and Peto, R., 1976, Mortality in relation to smoking: 20 years’ observation on male British doctors, Brit. Med. J., 2: 1525.PubMedCrossRefGoogle Scholar
  13. Epstein, M.A., 1976, Epstein-Barr virus — is it time to develop a vaccine program? J. Nat. Cancer Inst., 56: 697.PubMedGoogle Scholar
  14. Epstein, M.A., 1984, A prototype vaccine to prevent Epstein-Barr (EB) virus-associated tumours, Proc.Roy.Soc.B.Lond., 221: 1.CrossRefGoogle Scholar
  15. Epstein, M.A. and Achong, B.G., 1979, “The Epstein-Barr Virus”, M.A. Epstein and B.G. Achong, eds., Springer, Berlin.Google Scholar
  16. Epstein, M.A., Morgan, A.J., Finerty, S., Rändle, B.J. and Kirkwood, J.K., 1985, Protection of cotton-top tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine, Nature, 318: 287.PubMedCrossRefGoogle Scholar
  17. Henle, W. and Henle, G., 1969, The relation between the Epstein-Barr virus and infectious mononucleosis, Burkitt’s lymphoma and cancer of the postnasal space, E.African Med.J., 46: 402.Google Scholar
  18. Hummel, M., Thorley-Lawson, D.A. and Kieff, E., 1984, An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200), J.Virol., 49: 413.PubMedGoogle Scholar
  19. International Agency for Research on Cancer, 1985, An intervention study to evaluate the effectiveness of Hepatitis B vaccine for the prevention of hepatocellular carcinoma in a high risk population, IARC Working Paper 3/6:1.Google Scholar
  20. Kaaden, O.R. and Dietzschold, B., 1974, Alterations of the immunological specificity of plasma membranes of cells infected with Marek’s disease and turkey herpes viruses, J.Gen.Virol., 25: 1.PubMedCrossRefGoogle Scholar
  21. Kirkwood, J.K., Epstein, M.A. and Terlecki, A.J., 1983, Factors influencing population growth of a colony of cotton-top tamarins, Lab.Animals, 17: 35.CrossRefGoogle Scholar
  22. Kirkwood, J.K., Epstein, M.A, Terlecki, A.J. and Underwood, S.J., 1985, Rearing a second generation of cotton-top tamarins (Saguinus oedipus oedipus) in captivity, Lab.Animals, 19: 269.CrossRefGoogle Scholar
  23. Lowe, R.S., Keller, P.M., Keech, B.J., Davison, A.J., Whang, Y., Morgan, A.J., Kieff, E. and Ellis, R.W., 1987, Varicella-zoster virus as a live vector for the expression of foreign genes, Proc. Nat. Acad. Sci. USA, 84: 3896.PubMedCrossRefGoogle Scholar
  24. Mackett, M. and Arrand, J.R., 1985, Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340, EMBO, J., 4: 3229.Google Scholar
  25. Marek, J., 1907, Multiple Nervenentzündung (polyneuritis) bei Hühnern, Deutsch.Tierärztl Wschr., 15: 417.Google Scholar
  26. Miller, G., Shope, T., Coope, D., Waters, C., Pagano, J., Bornkamm, G.W. and Henle, W., 1977, Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum, antibody responses, demonstration of viral DNA, and characterization of viruses, J.Exp.Med., 145: 948.PubMedCrossRefGoogle Scholar
  27. Morein, B., Lovgren, K., Hogland, S. and Sundquist, B., 1987, The iscom: an immunostimulating complex, Immunol. Today, 8: 333.CrossRefGoogle Scholar
  28. Morgan, A.J., Finerty, S., Lovgren, K., Scullion, F.T. and Morein, B., 1988, Prevention of Epstein-Barr (EB) virus-induced lyhmphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into Iscoms, J.Gen.Virol., in press.Google Scholar
  29. Morgan, A.J., Mackett, M., Finerty, S., Arrand, J., Scullion, F. and Epstein, M.A., 1988, Recombinant vaccinia viruses expressing Epstein-Barr virus glycoprotein gp340 protect cottontop tamarins against EB virus-induced malignant lymphomas, J. Med. Virol., in press.Google Scholar
  30. Morgan, A.J., North, J.R. and Epstein, M.A., 1983, Purification and properties of the gp340 component of Epstein-Barr (EB) virus membrane antigen (MA) in an immunogenic form, J.Gen.Virol., 64: 455.PubMedCrossRefGoogle Scholar
  31. Moss, D.J. and Pope, J.H., 1972, Assay of the infectivity of the Epstein-Barr virus by transformation of human leucocytes in vitro, J. Gen. Virol., 17: 233.Google Scholar
  32. Niederman, J.C., Evans, A.S., Subrahmanyan, L. and McCollum, R.W., 1970, Prevalence, incidence and persistence of EB virus antibody in young adults, New Eng.J.Med., 282: 361.PubMedCrossRefGoogle Scholar
  33. North, J.R., Morgan, A.J., Thompson, J.L. and Epstein, M.A., 1982, Quantification of an EB virus-associated membrane antigen (MA) component, J.Virol. Methods, 5: 55.PubMedCrossRefGoogle Scholar
  34. Okazaki, W., Purchase, H.G. and Burmester, B.R., 1970, Protection against Marek’s disease by vaccination with a herpesvirus of turkeys, Avian Dis., 14: 413.PubMedCrossRefGoogle Scholar
  35. Payne, L.N., Fraxier, J.A. and Powell, P.C., 1976, Pathogenesis of Marek’s disease, in: “International Review of Experimental Pathology”, G.W. Richter and M.A. Epstein, eds., Academic Press, New York.Google Scholar
  36. Pereira, M.A., Blake, J.M. and Macrae, A.D., 1969, EB virus antibody at different ages, Brit.Med. J., 4: 526.PubMedCrossRefGoogle Scholar
  37. Purtilo, D.T., 1984, Immune deficiency and cancer. Epstein-Barr virus and lymphoproliferative malignancies, Plenum Medical Book Co., New York.Google Scholar
  38. Randle, B.J. and Epstein, M.A., 1984, A highly sensitive enzyme-linked immunosorbent assay to quantitate antibodies to Epstein-Barr virus membrane antigen gp340, J.Virol. Methods, 9: 201.PubMedCrossRefGoogle Scholar
  39. Rickinson, A.B., 1986, Cellular immunological responses to the virus infection in: “The Epstein-Barr virus: Recent Advances”, M.A. Epstein and B.G. Achong, eds., William Heinemann Medical Books, London.Google Scholar
  40. de Schryver, A., Klein, G., Hewetson, J., Rocchi, G., Henle, W., Henle, G., Moss, D.J. and Pope, J.H., 1974, Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti MA), Int. J. Cancer, 13: 353.PubMedCrossRefGoogle Scholar
  41. Schultz, L.D., Tanner, J., Hofmann, K., Emini, E., Kieff, E. and Ellis, R.W., 1987, Expression and analysis of EBV gp350 in yeast Saccharomyces cerevisiae, in: “Epstein-Barr Virus and Human Disease”, P.H. Levine, D.V. Ablashi, M. Nonoyama, G.R. Pearson and R. Glaser, eds., Humana Press, Clifton.Google Scholar
  42. Shanmugaratnam, K., 1971, Studies on the etiology of nasopharyngeal carcinoma, in: “International Review of Experimental Pathology”, G.W. Richter and M.A. Epstein, eds., Academic Press, New York.Google Scholar
  43. Takahashi, M., Otsuka, T., Okuno, Y., Asano, Y., Yazaki, T. and Isomura, S., 1974, Live varicella vaccine used to prevent the spread of varicella in children in hospital, Lancet ii: 1288.CrossRefGoogle Scholar
  44. de Thé, G., 1979, Demographic studies implicating the virus in the causation of Burkitt’s lymphoma; prospects for nasopharyngeal carcinoma, in: “The Epstein-Barr Virus”, M.A. Epstein and B.G. Achong, eds., Springer, Berlin.Google Scholar
  45. University Health Physicians and PHLS Laboratories, 1971, Infectious mononucleosis and its relationship to EB virus antibody, Brit. Med. J., iv: 643.Google Scholar
  46. Weibel, R.E., Neff, B.J., Kuter, B.J., Guess, H.A., Rothenburger, C.A. Fitzgerald, A.J., Connor, K.A., McLean, A.A., Hilleman, M.R. and Buynak, E.B., 1984, Live attenuated varicella virus vaccine: efficiency trial in healthy children, New Eng.J.Med., 310: 1409.PubMedCrossRefGoogle Scholar
  47. Whang, Y., Silberklang, M., Morgan, A., Munshi, S., Lenny, A.B., Ellis, R.W. and Kieff, E., 1987, Expression of Epstein-Barr virus gp350/220 gene in rodent and primate cells, J.Virol., 61: 1796.PubMedGoogle Scholar
  48. Zuckerman, A.J., 1985, Prevention of hepatocellular carcinoma by immunization against hepatitis B, in: “International Review of Experimental Pathology”, G.W. Richter and M.A. Epstein, eds., Academic Press, Orlando.Google Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • M. A. Epstein
    • 1
  1. 1.Nuffield Department of Clinical MedicineUniversity of OxfordOxfordUK

Personalised recommendations